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a b s t r a c t
Elevated serum levels of several cytokines have been reported in ovarian cancer. We have previously found
a diagnostic and prognostic value of hepatocyte growth factor (HGF).
The aims of this study were to evaluate the diagnostic and prognostic value of multiple serum cytokines
in women with ovarian tumors, and to examine possible associations between serum levels of cytokines
and the previously analyzed HGF. Preoperative levels of multiple cytokines were quantiﬁed by serum-based
immunoassays in 113womenwith apelvicmass: 57 carcinomas, 23 borderline tumors, and33benign ovarian
tumors. The results were related to clinicopathological parameters. Univariate and multivariate analyses of
ﬁve-year overall survival were performed.
Thewomenwith ovarian carcinoma had signiﬁcantly higher preoperative serum levels of cancer antigen 125
(CA 125), interleukin 8 (IL-8), and plasminogen activator inhibitor-1 (PAI-1) thanwomenwith benign ovarian
tumors. Serum IL-8 and PAI-1 levels were positively correlated to serum levels of HGF. In a multivariate
analysis of ﬁve-year overall survival, IL-8 had a prognostic impact.
Serum levels of IL-8 and PAI-1 were elevated in women with ovarian carcinoma compared to women with
benign ovarian tumors, and positively correlated to serum HGF levels in women with ovarian tumors. IL-8
also seemed to have a prognostic impact.
c© 2012 Elsevier B.V.
1. Introduction
Ovarian cancer is the most lethal gynecological malignancy in the
Western world. Although the survival has improved during the last
decade, only 40–45% of the patients are still alive ﬁve years after
diagnosis. Whereas the ﬁve-year survival is favourable for women
with early stage disease (about 90%), survival with advanced disease
is only around 20% [1]. Unfortunately, most cases are not diagnosed
until the disease is in an advanced stage. Early diagnosis would prob-
ably contribute to a drastic reduction inmortality. Different screening
strategies based on tumor markers have been evaluated, but an ef-
fective screening method has so far not been established. CA 125 is
themost usedmarker in themanagement of ovarian cancer [2,3], and
is detected in serum of more than 80%. It is, however, highly unspe-
ciﬁc, and can be elevated due to other conditions, both benign and
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malignant [4].
We have recently shown the diagnostic and prognostic value of
HGF in ovarian epithelial cancer [5]. HGF is a multifunctional growth
factor that enhances cell proliferation, motility, and angiogenesis [6].
ElevatedHGF levels have beendescribed in several human cancers [7–
10]. There are, however, few reports on possible associations between
serum levels of HGF and other cytokines in women with ovarian
cancer.
Active signal substances in inﬂammatory processes, such as cy-
tokines, growth factors, andprostaglandins, are involved in thepatho-
genesis of ovarian cancer [3,11], and elevated serum levels of several
cytokines have been reported in ovarian cancer [12–15]. Because no
single marker has shown adequate validity in screening for ovarian
cancer alone, research has been directed toward multi-marker pan-
els [16]. A diagnostic value of the combination of CA 125, IL-6, IL-8,
vascular endothelial growth factor (VEGF), epidermal growth factor
(EGF) andmonocyte chemotactic protein-1 (MCP-1)was, for example,
found with this approach [12,17].
The aims of the present studywere to analyze the validity ofmulti-
ple cytokines in predicting epithelial ovarian cancer in womenwith a
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pelvicmass, and to evaluate the prognostic impact of those cytokines.
Furthermore, we wanted to examine possible correlations between
serum levels of HGF and other cytokines in patients with ovarian
epithelial cancer.
2. Materials and methods
2.1. Patients
Blood samples collected fromapreviously described patient group
were applied [5]. The patient group consisted of women diagnosed
with a pelvicmass appointed for laparotomy at the Gynecological on-
cology unit at St. Olavs Hospital in Trondheim, Norway from October
15th 2001 to April 30th 2005. Blood sampleswere originally collected
from123women. In the present study, serumwas only available from
113 of these women, and of these 57 women had carcinoma, 23 bor-
derline, and 33 benign ovarian tumors. An informed consent was ob-
tained from all participants. Data regarding age at diagnosis and body
mass index (BMI) were registered in all cases. Histological type and
grade, residual tumor volume at the end of primary surgery, stage
of disease according to the International Federation of Gynecology
and Obstetrics (FIGO) guidelines [18], and follow-up were registered
for the carcinoma group. All histological slides were reviewed by one
pathologist (S.H.T), and classiﬁed according to the World Health Or-
ganization guidelines by histological type and grade of differentiation
[19].
2.2. Serum analyses
All serum samples were collected preoperatively. CA 125 was an-
alyzed with immunological methods as part of preoperative routine
serum analyses, and the results were extracted from the patients’
ﬁles. The sera were stored at –80 ◦C until analyses. No more than two
freeze–thaw cycles were allowed for each sample. The serum lev-
els of the following parameters were quantiﬁed using the Cytokine
Human 25-plex panel (Biosource International, Inc., Camarillo, CA,
USA): interleukin (IL)-1β, IL-1 Ra, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7,
IL-8, IL-10, IL-12, IL-13, IL-15, IL-17, tumor necrosis factor (TNF)α,
interferon (INF)α, INFγ, granulocyte-macrophage colony-stimulating
factor (GM-CSF), macrophage inﬂammatory protein (MIP)-1α, MIP-
1β, interferon gamma-induced protein (IP)-10, human monokine in-
ducedby INFγ (HU-MIG), eotaxin, rantes, andMCP-1. The serum levels
of adiponectin, resistin and PAI-I were analyzed by the Human Serum
Adipokine panel A kit, and the serum levels of leptin were quantiﬁed
using the Human Serum Adipokine panel B kit (Linco Research, Inc.
St. Charles, MI, USA). The Luminex 100 system (Luminex Corpora-
tion, Austin, TX, USA) was applied for the analyses, according to the
manufacturers’ instructions.
2.3. Statistical analyses
Statistical analyses were performed with the SPSS statistical soft-
ware program 17.0. For differences in serum cytokine levels between
carcinomas, borderline, and benign ovarian tumors, the Kruskal–
Wallis test was used. Sub-group analyses were performed with the
Mann–Whitney U test. Analysis of correlation between serum cy-
tokines andHGFwas performedwith the Spearman’s rank correlation
test.
In the group of carcinomas, comparison of serum cytokine lev-
els between the groups of different histological type and grade was
performed with the Kruskal–Wallis test. The Cox proportional haz-
ard regression model was used to evaluate the effect of explanatory
variables on overall survival. Five-year overall survival was calculated
from the date of primary surgery, to the date of death or status after
ﬁve years. In the univariate analyses, age, stage, histological type and
grade, residual tumor volume, and the cytokines thatwere elevated in
Table 1
Characteristics of the cases included (N = 113).
No. of tumors %
Cancer 57
FIGO stage
I 19 33
II 3 5
III 29 51
IV 6 11
Histological type
Serous 28 49
Mucinous 2 3
Endometroid 13 23
Clear cell 6 11
Mixed 6 11
Undifferentiated 2 3
Histological grade (G)*
G1 6 12
G2 12 23
G3 33 65
Borderline 23
Serous 15
Mucinous 6
Clear cell 1
Mixed 1
Benign 33
Epithelial/functional
cyst
20 61
Dermoid cyst 2 6
Endometriosis 1 3
Ovarian ﬁbroma 7 21
Uterine myoma 3 9
the group of carcinomas were the parameters analyzed. In the analy-
ses of histology, we chose to compare serous and non-serous tumors.
The parameters with p-values <0.2 in the univariate analyses were
included in a multivariate analysis. In all analyses, p-values <0.05
were considered signiﬁcant.
3. Results
3.1. Patients characteristics
The mean age at diagnosis was 63.8 years (±11.6 years) in the
carcinoma group, 54.8 years (±14.4 years) in the borderline group,
and 59.2 years (±13.6 years) in the benign group. There was no sig-
niﬁcant difference in median BMI between the groups (carcinomas
25.8 (17.0–43.4) kg/m2, borderline 25.1 (20.7–34.4) kg/m2, benign
24.4 (17.5–35.1) kg/m2, p = 0.346). Other characteristics are listed
in Table 1.
3.2. Serum analyses
The serum levels of CA 125, IL-8, adiponectin, resistin, PAI-1 and
leptin (median and range) in the groups of carcinomas, borderline and
benign tumors are listed in Fig. 1. Interleukin (IL)-1β, IL-1 Ra, IL-2, IL-
2R, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12, IL-13, IL-15, IL-17, tumor necro-
sis factor (TNF)α, interferon (INF)α, INFγ, granulocyte–macrophage
colony-stimulating factor (GM-CSF), macrophage inﬂammatory pro-
tein (MIP)-1α, MIP-1β, interferon gamma-induced protein (IP)-10,
human monokine induced by INFγ (HU-MIG), eotaxin, rantes, and
MCP-1 were detected in less than 80% of the samples andwere there-
fore not included in further analyses. We demonstrate signiﬁcant dif-
ferences between carcinomas, borderline tumors, and benign tumors
in the serum levels of CA 125, IL-8, and PAI-1 (Fig. 1).
In separate analyses, including only the carcinomas, there were
no differences in serum levels of CA 125, IL-8 or PAI-1 related to
192 Guro Aune et al. / Results in Immunology 2 (2012) 190–195
Fig. 1. Median serum levels and range of (A) CA 125, (B) HGF, (C) IL-8, (D) PAI-1, (E) leptin, (F) resistin and (G) adiponectin levels in patients with carcinoma, borderline, and benign
tumors of the ovary (N = 113). *: comparison carcinomas/benign; ‡: comparison carcinomas/borderline; †: comparison borderline/benign, signiﬁcant differences, p<0.05.
histological type or tumor grade. The cases of advanced stage (FIGO
stages III and IV) had signiﬁcantly higher serum levels of CA 125 and
IL-8, compared to the cases of early stage cancer (FIGO stages I and II)
(median CA125 of 932 vs. 377KU/L, p = 0.005 and median IL-8 of 40
vs. 30pg/mL, p = 0.049, respectively).
As mentioned above, we have previously measured serum HGF
in the same study population (11). Of the 123 women included in
the previous study, sera were only available from 113 women. The
median serum HGF level of the 113 women included in the present
study was 2717.4 (55–16,689) pg/ml in the carcinoma group, 1668
(177–7955) pg/ml in the borderline group, and 1271 (74–4644) pg/
ml in the benign group. We found a signiﬁcant positive correlation
between serum levels of HGF and IL-8 (r = 0.206, p = 0.029), and
between HGF and PAI-1 (r = 0.212, p = 0.024). In the analyses of
the potential to predict malignancy, the median serum HGF and IL-8
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Table 2
Univariate analyses of potential prognostic factors for survival in women with ovarian
carcinoma (N = 57).
Variable HR 95% CI for HR p-Value
Early stage 1
Advanced stage 9.115 2.740–30.322 <0.001
Non-serous
histology
1
Serous
histology
3.329 1.634–6.738 0.01
Grade 1 1
Grade 2 2.077 0.431–10.009 0.362
Grade 3 2.281 0.532–9.783 0.267
Residual tumor
<1 cm
1
Residual tumor
≥1 cm
6.548 2.488–17.421 <0.001
Age 1.026 0.993–1.060 0.123
CA 125 1.000 1.000–1.000 0.030
IL-8 1.006 1.002–1.010 0.007
PAI-1 1.003 0.994–1.012 0.489
Table 3
Multivariate analysis of potential prognostic factors for survival inwomenwith ovarian
carcinomas (N = 57).
Variable HR 95% CI for HR p-Value
Early stage 1
Advanced stage 7.656 1.217–48.177 0.030
Non-serous
histology
1
Serous
histology
1.264 0.524–3.048 0.602
Residual tumor
<1 cm
1
Residual tumor
≥1 cm
1.082 0.230–5.081 0.920
Age 1.038 1.001–1.078 0.046
CA 125 1.000 1.000–1.000 0.668
IL-8 1.004 1.000–1.009 0.029
levels in the benign group were chosen as reference values, and cut-
off values were determined at 2SD above these values; 3457pg/ml
(1271+2186) and59pg/ml (23+36), respectively.HGFand IL-8 levels
below these cut-offs were deﬁned as normal, and levels above were
deﬁned as elevated. Of the women with carcinoma, 20 women had
elevated HGF levels, and 17 women had elevated IL-8 levels. When
we combined the two markers, 30 of the 57 women with carcinoma
had either elevated HGF or elevated IL-8 levels.
3.3. Survival
The ﬁve-year overall survival for all women with carcinoma was
49%. In the women with early stage cancer, the ﬁve-year overall sur-
vival was 86%, and in women with advanced stage 26%.
In the univariate analyses of survival, the following parameters
were statistically signiﬁcant: stage of disease, histological type, resid-
ual tumor volume, and serum level of CA 125 and IL-8 (Table 2). In
a multivariate analysis, age, stage of disease and serum IL-8 level
reached statistical signiﬁcance (Table 3). A Kaplan–Meier plot of 5-
year survival in cases with advanced stage ovarian epithelial cancer
related to IL-8 level can be seen in Fig. 2.
4. Discussion
In the present studywe found that the serum levels of CA 125, IL-8,
and PAI-1 were signiﬁcantly higher in womenwith ovarian epithelial
cancer compared to women with benign ovarian tumors.
Most ovarian carcinomas are thought to originate from the surface
epithelium or postovulatory inclusion cysts. Damages of the ovarian
Fig. 2. 5-year survival in advanced stage epithelial ovarian cancer in cases ≤2SD and
>2SD from reference value.
surface epithelium during ovulation lead to repair processes that at-
tract leukocytes, stimulate release of inﬂammatory cytokines and ni-
trous oxide, DNA repair, and tissue restructuring [20]. Repeated ovu-
lations with following repair processes increase the risk of errors in
replication, which may cause cancer development [20]. Activation of
the nuclear factor κB (NF-κB), a family of signal-activated transcrip-
tion factors, by proinﬂammatory cytokines may promote carcino-
genesis, and thus represent a link between inﬂammation and cancer
development. NF-κB activation regulates genes that promote tumor
cell proliferation, survival,migration, inﬂammation, and angiogenesis
[21].
Elevated serum IL-8 levels in women with ovarian cancer have
been reported in several studies [17,22–25]. IL-8 is a CXC-family
chemokine, promoting angiogenesis, invasion, and cancer metastasis
by binding to the receptors CXCR1 and CXCR2 [25,26]. Induction of
IL-8 expression ismainlymediated byNF-κB [26].Wehave previously
shown HGF to be a marker for ovarian epithelial cancer and an indi-
cator of poor prognosis [5]. By binding to its receptor c-Met, HGF has
been reported to enhance NF-κB DNA binding and NF-κB-dependent
transcriptional activity [27–29]. Previous studies have reported both
decreased and increased cytokine expression in response to HGF. HGF
inhibited the NF-κB-mediated proinﬂammatory cytokine expression
in a renal tubular cell line [30]. Furthermore, HGF reduced allergic
airway inﬂammation in asthma by, among other mechanisms, sup-
pressing the T cell cytokine production [31]. On the contrary, HGF
enhanced the IL-1-stimulated secretion of IL-8 and MCP-1 in an ep-
ithelial colon cell line [32]. Blocking angiogenesis is a novel treatment
in platinum resistant ovarian cancer [33]. Both HGF and IL-8 are me-
diators of angiogenesis. In the present study we found a statistically
signiﬁcant positive correlation between the serum levels of HGF and
IL-8, indicating that HGF may be involved in the regulation of IL-8
expression in ovarian epithelial tumors. In analyses of the potential
to predict malignancy, we were able to detect more womenwith car-
cinoma when both HGF and IL-8 were included, compared to either
marker alone.
Some of the markers analyzed in this study (leptin, adiponectin,
resistin and PAI-1) are also classiﬁed as adipokines. Adipokines are
a group of hormones synthesized by adipose tissue, which exert
paracrine and endocrine effects in the regulation of metabolism,
immunity and inﬂammation. Adipokines are also involved in hu-
man diseases, such as diabetes mellitus and cardiovascular disease,
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and in processes of angiogenesis and tumor growth. There have
been conﬂicting results regarding the diagnostic value of circulating
adipokines in ovarian cancer [34–36]. In the present study, women
with ovarian carcinomas had higher serum PAI-1 levels than women
with benign ovarian tumors. Higher expression of PAI-1 has been de-
scribed in ovarian cancer tissue compared to benign ovarian tumor
tissue [37], and a prognostic impact of PAI-1 expression in tumor
tissue has been described in advanced stage cancers [37]. On the
contrary, Abendstein et al. were not able to ﬁnd a prognostic value
of serum PAI-1 levels in women with recurrent ovarian cancer [38].
Little is, however, known about the diagnostic value of serum PAI-
1 levels in women with ovarian tumors. Havrilesky et al. described
a marker panel, including CA 125, HE4, Glycodelin, Plau-R, MUC-1,
and PAI-1 to have a sensitivity of 80.5% and a speciﬁcity of 96.5% in
predicting early stage ovarian cancer [39].
In the present study, we found no differences in serum lev-
els of adiponectin, leptin, or resistin between women with ovarian
carcinoma, borderline, or benign tumors. The adiponectin results
are in contrast to the inverse relation between circulating levels of
adiponectin and cancer found in several other malignant conditions
[40–42]. A diagnostic value of serum leptin was found in a study by
Visintin et al., where leptin was included in a panel of six markers
[35]. Vrzalova et al. analyzed the same marker panel, but they were
not able to replicate the results. Our data are in accordance with
Vrzalovas’ study, and with a study by Serin et al. [34,36]. The lack of
difference in adiponectin and leptin levels between the groups could
be explained by the similar BMI.
The ﬁve-year overall survival was 49% in the present study, which
is in accordance with previous reports [43–45]. In addition to stage
of disease, which is a well-documented prognostic factor in ovarian
cancer [44], IL-8 had an impact on prognosis in both univariate and
multivariate analyses.We foundnoprognostic impact of serumPAI-1,
which is in line with the previous report fromwomen with recurrent
ovarian cancer [38]. This result is, however, in contrast to reports of
a poor prognosis related to high PAI-1 expression in ovarian cancer
tissue [37].
In conclusion, serum levels of IL-8 and PAI-1 were signiﬁcantly
higher in women with ovarian carcinoma compared to women with
benign ovarian tumors. Serum levels of IL-8 and PAI-1 were found to
correlate positively to serum levels of HGF inwomenwith ovarian tu-
mors in our study. Further studies are needed to evaluate the relation
between HGF and IL-8 in ovarian carcinogenesis. This relation could
play a role in the blocking of angiogenesis.
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